The Latest Breaking News from EMA

The European Union's drug regulator needs to do more to tackle shortages of some widely-used antibiotics in the region, according to a letter from a group of European patient and consumer organisations reviewed by Reuters on Tuesday.

A variety of different roles are being advertised

The facility is expected to open in just over a year

The European Medicines Agencies (EMA) recommended European countries include new warnings on labels and in package inserts of analgesics, or pain killers, that combine codeine and ibuprofen. This recommendation was agreed at the last meeting of the Pharmacovigilance Risk Assessment Committee (PRAC), held at the end of September 2022.

The European Medicines Agency is recommending that a dengue vaccine made by the Japanese pharmaceutical Takeda be authorized, in a move that could provide a new tool for millions worldwide against the potentially fatal disease

Holidaymakers planning a half-term break need to be aware that Spain is the only EU country where travel restrictions are still in place

Despite the Fed's aggressive interest rate hikes, the job market remains strong. However, given the mounting recessionary fears, it may be prudent to invest in UnitedHealth Group (UNH) and Biogen (BIIB), based on their solid fundamentals and impressive growth prospects. Continue Reading….

The Fed’s aggressive monetary policies are raising recession fears. Amid such an environment, we think investors could consider adding AbbVie (ABBV), Pfizer (PFE), and Coca-Cola (KO) to their portfolios for stable returns. Read on to learn more….

An official at the European Union's drugs regulator said on Tuesday the COVID-19 pandemic was not over, contradicting U.S. President Joe Biden, and that a planned vaccination campaign in the region during the cold season was key to fighting it.

People in Europe should take whatever COVID-19 booster is available to them in the coming months, Emer Cooke, Executive Director of the European Medicines Agency (EMA), said in a Reuters Next Newsmaker interview ahead of an expected autumn rise in infections.

The healthcare industry is anticipated to grow significantly in the coming years, thanks to strong demand amid rising chronic diseases, technological advancements, and rising healthcare spending. Therefore, we think fundamentally sound healthcare companies Pfizer (PFE), GSK Plc (GSK), and Teva Pharmaceutical (TEVA), which are currently trading under $50, could be…